Clinical Trial Update: Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Yttrium-90 ibritumomab tiuxetan added to high-dose BEAM chemotherapy followed by autologous stem cell transplant in patients with relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Carmustine (carmustine)
• Etoposide (Etoposide)
• Melphalan (Melphalan)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-06